SAIC Awarded Contract by Defense Health Services System
Science Applications International Corporation(NYSE: SAI) announced today it was awarded a prime contract by the Defense Health Services System (DHSS) to provide ongoing sustainment, operation and maintenance of the TRICARE Online (TOL) system and expand Blue Button capability in support of the Program Executive Office (PEO) Clinical Support Division. The single-award cost-plus fixed-fee (CPFF) contract has a six-month base period of performance, two one-year options, one-three month transition period, and a total contract value of approximately $11 million, if all options are exercised. Work will be performed primarily in San Diego, Calif. and Falls Church, Va.
TOL is the military health system's internet point of entry that provides all TRICARE beneficiaries access to available healthcare services through an enterprise-wide secure portal. The TOL Blue Button is an open-government initiative that provides authorized users convenient access to their personal health information.
Under the contract, SAIC will expand Blue Button capability including radiology results, vital signs, immunizations, outpatient discharge summary, surgical results, insurance and other patient information to provide civilian partner information as available through the Virtual Lifetime Electronic Record (VLER) exchange service; allow reconciliation of active medications for download and/or print; include Personal Health Journaling (PHJ) in collaboration with the Veterans Health Administration; and expand TOL to include mobile device access and appointment center, and prescription refill capabilities to incorporate Patient Centered Medical Home (PCMH) requested improvements.
"We're proud to continue our support of the TOL Sustainment team and the Blue Button initiative, enabling patients to have greater control of their own health record and medical history to help improve patient care," said Steve Comber, SAIC senior vice president and business unit general manager.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.